title: Tolterodine immediate release improves sexual function in women with overactive bladder.
abstract: BACKGROUND
  Quality of life studies indicate that overactive bladder (OAB) has a greater negative impact on everyday life than other serious conditions such as diabetes. The detrimental effect of OAB on female sexual health is more prominent than urinary incontinence. We know that tolterodine immediate release (IR) has a beneficial effect on urinary symptoms in OAB.
  
  
  OBJECTIVE
  To evaluate the impact of tolterodine IR on sexual function in patients with OAB.
  
  
  METHODS
  A total of 30 sexually active women with OAB from 20 to 52 years were included. All patients filled out the International Consultation on Incontinence Questionnaire (ICIQ) and the Arizona Sexual Experience Scale (ASEX) before treatment with tolterodine IR and at the end of each month of treatment until 3 months.
  
  
  METHODS
  Expected outcomes were improvements in the ICIQ and ASEX total score. All ASEX items were expected to improve individually. These improvements indicate better sexual function after treatment. Results. The mean of the total ASEX score improved relative to baseline in the first (P<0.01), second (P<0.01), and third (P<0.01) follow-up. The mean of scores for sexual desire, arousal, vaginal lubrication, orgasm, and orgasm satisfaction improved significantly (P<0.01) with each follow-up.
  
  
  CONCLUSIONS
  Tolterodine IR significantly improves sexual function of women with OAB. Improvement is seen in all domains of sexual function.
authors.affiliation: Urology Department, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Sakineh
authors.initials: S
authors.lastname: Hajebrahimi
authors.forename: Arash
authors.initials: A
authors.lastname: Azaripour
authors.forename: Homayoun
authors.initials: H
authors.lastname: Sadeghi-Bazargani
mesh_terms: D000328:Adult; D001143:Arousal / Q000187:drug effects; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D003408:Cresols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009948:Orgasm / Q000187:drug effects; D010665:Phenylpropanolamine / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology; D012725:Sexual Behavior / Q000187:drug effects*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000523:psychology; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000517:prevention & control; D014549:Urinary Incontinence / Q000188:drug therapy / Q000523:psychology; D055815:Young Adult
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate